Home > Newsletters > Drug Industry Daily > Battle Lines Drawn in Brand vs. Generic Fight Over Cost-Saving Efforts in PDUFA Bills
Drug Industry Daily
June 8, 2012 | Vol. 11 No. 113
Battle Lines Drawn in Brand vs. Generic Fight Over Cost-Saving Efforts in PDUFA Bills
Generic-drug makers have been rooting for a provision in the Senate’s FDA user fee bill that would expand access to REMS-restricted brand drugs to aid them in developing generic versions.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.